Skip to main content
Year archive

Cellectis — 2021 filings

All 103 regulatory filings released by Cellectis (ALCLS) in 2021, sourced directly from the official regulator.

103 Filings
2021 Period
2021 filings (103)
Filing Released Lang
FORM 6-K
Foreign Filer Report
2021-12-13 English
Cellectis Reports Encouraging Clinical Data from BALLI-01 Study in Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia, and Preclinical Data from TALGlobin01 at the 63rd American Society of Hemato
Earnings Release FY 2021
2021-12-11 English
6-K
Foreign Filer Report
2021-12-07 English
Monthly information on share capital and company voting rights
Declaration of Voting Results & Voting Rights Announcements
2021-12-06 English
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
Declaration of Voting Results & Voting Rights Announcements
2021-12-06 French
6-K
Foreign Filer Report
2021-11-24 English
FORM 6-K
Foreign Filer Report
2021-11-18 English
Cytovia and Cellectis Expand Their TALEN® Gene-Edited iNK Partnership to Enable Broader Collaboration in China
Regulatory Filings
2021-11-18 English
Cellectis et Cytovia étendent leur partenariat en Chine pour développer des cellules NK dérivées d’iPSC génétiquement modifiées par TALEN®
Regulatory Filings
2021-11-18 French
Society for Immunotherapy of Cancer (SITC) : Cellectis présente les premières données précliniques de UCARTMESO, son produit candidat de cellules CAR-T allogéniques ciblant la mésothéline pour le trai
Regulatory Filings
2021-11-12 French
Cellectis Presents First Preclinical Data on UCARTMESO, an Allogeneic CAR-T Cell Product Candidate Targeting Mesothelin to Treat Solid Tumors at the Annual Meeting of the Society for Immunotherapy of
Environmental & Social Information
2021-11-12 English
FORM 6-K
Foreign Filer Report
2021-11-12 English
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
Declaration of Voting Results & Voting Rights Announcements
2021-11-08 French
Monthly information on share capital and company voting rights
Declaration of Voting Results & Voting Rights Announcements
2021-11-08 English
6-K
Foreign Filer Report
2021-11-04 English
FORM 6-K
Foreign Filer Report
2021-11-04 English
Cellectis publie ses résultats financiers pour le troisième trimestre et pour les neuf premiers mois de l’année 2021
Earnings Release 9M 2021
2021-11-04 French
Cellectis Provides Business Update and Reports Financial Results for Third Quarter and First Nine Months 2021
Earnings Release 9M 2021
2021-11-04 English
FORM 6-K
Foreign Filer Report
2021-11-04 English
American Society of Hematology (ASH) : Cellectis annonce la publication de deux abstracts portant sur des résultats cliniques préliminaires actualisés de son essai BALLI-01 et des premiers résultats p
Regulatory Filings
2021-11-04 French
Cellectis Announces Release of Abstracts at ASH Showcasing Updated Preliminary Clinical Data from BALLI-01 Study and First Preclinical Data from TALGlobin01
Regulatory Filings
2021-11-04 English
FORM 6-K
Foreign Filer Report
2021-10-28 English
Cellectis organise une conférence téléphonique pour présenter ses résultats financiers du troisième trimestre 2021 le vendredi 5 novembre à 14h00 CET
Earnings Release Q3 2021
2021-10-28 French
Cellectis to Hold Third Quarter Earnings Call on Friday, November 5, 2021 at 8AM EDT
Earnings Release 9M 2021
2021-10-28 English
FORM 6-K
Foreign Filer Report
2021-10-19 English
Cellectis Presents Initial Preclinical Data on Two Novel Gene Therapies for Patients with RAG1 Severe Combined Immunodeficiency (SCID) and Hyper IgE syndrome at ESGCT 2021
Regulatory Filings
2021-10-19 English
Cellectis présente à l‘ESGCT les premières données précliniques de deux nouvelles thérapies géniques pour les patients atteints d’immunodéficience combinée sévère RAG1 (SCID) et du syndrome Hyper IgE
Regulatory Filings
2021-10-19 French
FORM 6-K
Foreign Filer Report
2021-10-12 English
Cellectis présentera des données précliniques sur l’activité anti-tumorale de son produit candidat UCARTMESO à la Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
Environmental & Social Information
2021-10-12 French
Cellectis to Present Preclinical Data on UCARTMESO Supporting Anti-Tumor Activity at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
Earnings Release FY 2020
2021-10-12 English
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
Declaration of Voting Results & Voting Rights Announcements
2021-10-11 French
Monthly information on share capital and company voting rights
Share Issue/Capital Change
2021-10-11 English
6-K
Foreign Filer Report
2021-10-08 English
6-K
Foreign Filer Report
2021-10-05 English
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
Share Issue/Capital Change
2021-09-10 French
Monthly information on share capital and company voting rights
Share Issue/Capital Change
2021-09-10 English
6-K/A
Foreign Filer Report
2021-08-31 English
FORM 6-K
Foreign Filer Report
2021-08-26 English
Cellectis annonce sa participation à cinq conférences investisseurs
Regulatory Filings
2021-08-26 French
Cellectis Announces Participation in Five Investor Conferences
Regulatory Filings
2021-08-26 English
S-8
Registration Form
2021-08-05 English
6-K
Foreign Filer Report
2021-08-05 English
FORM 6-K
Foreign Filer Report
2021-08-05 English
Cellectis publie ses résultats financiers pour le deuxième trimestre et le premier semestre 2021
Earnings Release H1 2021
2021-08-05 French
Cellectis Provides Business Update and Reports Financial Results for Second Quarter and First Six Months 2021
Earnings Release Q2 2021
2021-08-05 English
Monthly information on share capital and company voting rights
Share Issue/Capital Change
2021-08-02 English
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
Share Issue/Capital Change
2021-08-02 French
Cellectis organise une conférence téléphonique pour présenter ses résultats financiers du deuxième trimestre 2021 le vendredi 6 août à 14h00 CET
Report Publication Announcement
2021-07-29 English
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
Share Issue/Capital Change
2021-07-12 French
Monthly information on share capital and company voting rights
Share Issue/Capital Change
2021-07-12 English
FORM 6-K
Foreign Filer Report
2021-06-14 English
À l’occasion des Innovation Days, Cellectis dévoile ses nouveaux produits candidats en développement, sa plateforme de chirurgie du génome .HEAL, ainsi que ses capacités de production
Investor Presentation
2021-06-14 French
Cellectis’ Innovation Days event highlighted New Product Development, New Genome Surgery Platform .HEAL, and Manufacturing Capabilities
Investor Presentation
2021-06-14 English
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
Share Issue/Capital Change
2021-06-09 French
Monthly information on share capital and company voting rights
Share Issue/Capital Change
2021-06-09 English
FORM 6-K
Foreign Filer Report
2021-06-02 English
Cellectis S.A. Reports Results from Annual Shareholders’ General Meeting Held on June 1, 2021
AGM Information
2021-06-02 English
Résultats de l’Assemblée Générale Mixte des Actionnaires de Cellectis S.A. du 1 juin 2021
AGM Information
2021-06-02 French
FORM 6-K
Foreign Filer Report
2021-05-24 English
FORM 6-K
Foreign Filer Report
2021-05-19 English
FORM 6-K
Foreign Filer Report
2021-05-11 English
Cellectis and Sanofi partner on alemtuzumab as lymphodepletion agent for allogeneic CAR-T
Earnings Release FY 2021
2021-05-11 English
Monthly information on share capital and company voting rights
Share Issue/Capital Change
2021-05-10 English
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
Share Issue/Capital Change
2021-05-10 French
FORM 6-K
Foreign Filer Report
2021-05-06 English
FORM 6-K
Foreign Filer Report
2021-05-06 English
Cellectis Provides Business Update and Reports Financial Results for First Quarter 2021
Earnings Release Q1 2021
2021-05-06 English
Cellectis publie ses résultats financiers du premier trimestre 2021
Earnings Release Q1 2021
2021-05-06 French
6-K
Foreign Filer Report
2021-04-27 English
FORM 6-K
Foreign Filer Report
2021-04-26 English
Cellectis’ Annual Shareholders’ General Meeting to be Held on June 1, 2021
AGM Information
2021-04-26 English
L’Assemblée Générale Mixte de Cellectis se tiendra à huis-clos le 1 juin 2021
AGM Information
2021-04-26 French
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
Share Issue/Capital Change
2021-04-12 French
Monthly information on share capital and company voting rights
Share Issue/Capital Change
2021-04-12 English
FORM 6-K
Foreign Filer Report
2021-04-09 English
Cellectis réalise un placement d’ADSs pour 47 millions de dollars sur le Nasdaq dans le cadre de son programme At the Market
Share Issue/Capital Change
2021-04-09 French
Cellectis Completes Sale of $47 million through its ATM program
Share Issue/Capital Change
2021-04-09 English
FORM 6-K
Foreign Filer Report
2021-03-29 English
Cellectis met en place un programme At the Market sur le Nasdaq
Share Issue/Capital Change
2021-03-29 French
Cellectis Establishes an At-The-Market (ATM) Program on Nasdaq
Capital/Financing Update
2021-03-29 English
6-K
Foreign Filer Report
2021-03-29 English
424B5
Prospectus
2021-03-29 English
Monthly information on share capital and company voting rights
Share Issue/Capital Change
2021-03-12 English
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
Share Issue/Capital Change
2021-03-12 French
S-8 POS
Regulatory Filings
2021-03-04 English
20-F
Annual Report FY 2020
2021-03-04 English
FORM 6-K
Foreign Filer Report
2021-03-04 English
Cellectis publie ses résultats financiers du quatrième trimestre 2020 et de l’exercice 2020
Earnings Release Q4 2020
2021-03-04 French
Cellectis Provides Business Update and Reports 4th Quarter and Full Year 2020 Financial Results
Earnings Release Q4 2020
2021-03-04 English
Cellectis to Hold Fourth Quarter 2020 Earnings Call on Friday, March 5, 2021 at 8:00AM EST
Earnings Release Q4 2020
2021-02-25 English
Cellectis organise une conférence téléphonique pour présenter ses résultats financiers du quatrième trimestre 2020 le vendredi 5 mars à 14h00 CET
Report Publication Announcement
2021-02-25 French
FORM 6-K
Foreign Filer Report
2021-02-19 English
SC 13G/A
Major Shareholding Notification
2021-02-16 English
SEC SCHEDULE 13G
Major Shareholding Notification
2021-02-16 English
FORM 6-K
Foreign Filer Report
2021-02-16 English
Cytovia Therapeutics and Cellectis Partner to Develop TALEN® Gene-Edited iPSC-Derived Natural Killer Cells
Regulatory Filings
2021-02-16 English
Cytovia Therapeutics et Cellectis s’associent pour développer des cellules NK dérivées d’iPSC génétiquement modifiées par TALEN®
Regulatory Filings
2021-02-16 French
SC 13D/A
Major Shareholding Notification
2021-02-12 English
Cellectis : Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
Declaration of Voting Results & Voting Rights Announcements
2021-02-10 French
Cellectis: Monthly information on share capital and company voting rights
Declaration of Voting Results & Voting Rights Announcements
2021-02-10 English
Major Shareholding Notification 2021
Major Shareholding Notification
2021-02-08 English
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
Share Issue/Capital Change
2021-01-06 French
Monthly information on share capital and company voting rights
Share Issue/Capital Change
2021-01-06 English